Australia markets close in 5 hours 31 minutes

Grifols, S.A. (GIFLF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
10.910.00 (0.00%)
At close: 03:20PM EST
Full screen
Trade prices are not sourced from all markets
Previous close10.91
Bid0.00 x 0
Ask0.00 x 0
Day's range10.91 - 10.91
52-week range9.07 - 15.80
Avg. volume951
Market cap7.024B
Beta (5Y monthly)0.68
PE ratio (TTM)272.75
EPS (TTM)0.04
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date03 June 2021
1y target estN/A
  • Zacks

    GRFS or ZTS: Which Is the Better Value Stock Right Now?

    GRFS vs. ZTS: Which Stock Is the Better Value Option?

  • GlobeNewswire

    Grifols announces positive topline phase 3 fibrinogen clinical trial results

    In the AdFIrst study, Biotest's fibrinogen concentrate (FC), BT524, met the primary endpoint, demonstrating its effectiveness in treating acquired fibrinogen deficiency (AFD) as equivalent to standard of care, while maintaining an excellent safety profileRegulatory approval process in Europe and United States set to begin in Q4 2024. It would be the first FC approved for an AFD indication in the U.S. in a global market for AFD with an estimated potential of USD 800 millionThis milestone is part

  • Zacks

    Here's Why Grifols (GRFS) Is a Great 'Buy the Bottom' Stock Now

    Grifols (GRFS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.